Richard Larson, M.D.
University of Chicago
5841 S Maryland Ave
MC2115
Chicago,
IL
USA
60637
Papers:
WHAT IS THE MOST COST-EFFECTIVE STRATEGY FOR TREATING CHRONIC MYELOID LEUKEMIA AFTER IMATINIB LOSES PATENT EXCLUSIVITY IN THE UNITED STATES?
Student?
yes
SMDM Member?
yes